Adjunctive therapy for glucose control in patients with type 1 diabetes

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• Type 1 diabetes mellitus (T1DM) involves insulin deficiency, often failing to meet glycemic goals with insulin therapy alone.
• Insulin therapy for T1DM can cause adverse effects such as hypoglycemia and weight gain.
• Adjunctive therapies are explored to enhance glycemic control and mitigate side effects in T1DM management.

Purpose of the Study:

• To review and evaluate various adjunctive therapies used in conjunction with insulin for Type 1 Diabetes Mellitus.
• To assess the efficacy and safety profiles of different drug classes as add-on treatments for T1DM.

Main Methods:

• Review of existing literature on adjunctive therapies for T1DM.
• Analysis of the mechanisms of action, benefits, and risks of pramlintide, metformin, GLP-1 RAs, and SGLT-2 inhibitors.
• Consideration of patient-specific characteristics in treatment selection.

Main Results:

• Pramlintide improves glycemic control but carries risks of hypoglycemia and requires extra injections.
• Metformin offers an oral option, potentially reducing blood glucose, especially in overweight patients, with minimal hypoglycemia risk.
• GLP-1 RAs lower postprandial glucose and insulin dose, promoting weight loss, but are costly and can cause nausea and hypoglycemia.
• SGLT-2 inhibitors improve glycemic control and promote weight loss with low hypoglycemia risk but may increase diabetic ketoacidosis risk in T1DM.

Conclusions:

• Adjunctive therapies offer potential benefits for T1DM management beyond insulin alone.
• Selection requires careful consideration of patient-specific factors, efficacy, and adverse event profiles.
• Close monitoring, insulin dose adjustment, and patient education are vital for safe and effective use of these agents.